Retractable Technologies Q1 net sales fall to $7.6M; operating loss widens to $3.0M

RETRACTABLE TECHNOLOGIES INC

2024-Q1 EPS reported $0.01 revenue$7,599,363

Net sales $7.6M, down 31% from $11.0M in Q1 2023 due to lack of COVID vaccine syringe sales.
Operating loss $3.0M vs $2.7M; loss widened despite 12.9% decrease in operating expenses.
Domestic sales rose 22.5% to $6.6M; international sales fell 82.8% to $1.0M.
Unrealized gain on investments of $1.7M impacted net income; provision for income taxes $86K.
New 50% tariff on syringes/needles expected in Q3 2024; over 90% of products sourced from China.

item 5.07 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

RETRACTABLE TECHNOLOGIES INC shareholders approved Election of Three Class 2 Directors at the 2024-05-10 meeting.

Proposal: director election
Outcome: passed
Meeting: 2024-05-10

Exact text from the filing

Voting results are shown in the table below. Votes For Votes Withheld Abstentions and Broker Non-Votes CLASS 2 DIRECTORS Thomas J. Shaw 19,813,088 865,410 0 Walter O. Bigby, Jr. 19,085,632 1,592,866 0 John W. Fort III 19,718,001 960,497 0

View on SEC.gov

Browse all shareholder votes →

RETRACTABLE TECHNOLOGIES INC filing history →

Source: SEC EDGAR

accession 0001104659-24-062057

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.